A Phase 3 interventional study of Golimumab in Axial Spondyloarthritis, sponsored by University Ghent. Completed at 3 sites in Belgium. Open to participants aged 18 Years to 46 Years. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by University Ghent · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Axial Spondyloarthritis with a site in Belgium — 1 open to participants now, 2 under way, 1 of them phase 3. Axial Spondyloarthritis · Belgium.
Among the 17 studies in Axial Spondyloarthritis with a site in Belgium, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 8th registered.
187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.
Browse Axial Spondyloarthritis studies →1 of the 17 studies in Axial Spondyloarthritis with a site in Belgium is open now. Recruiting first, the newest first:
Grey Wolf Therapeutics · Sites in Belgium, Australia, Germany and 3 more countries
Ages 18–65
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 46 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 106 across 123 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 383 across the 13 interventional studies, 694 across the 4 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 17 have an industry lead sponsor. The 10 most frequent:
University Ghent is the lead sponsor of 350 studies on the registry; 86 are open to participants now.
University Ghent has 1 study filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Axial Spondyloarthritis with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The hypothesis of the study is that the presence of (subclinical) gut inflammation at baseline in patients with early active axial spondyloarthritis predisposes to a more severe disease defined as more need to use anti-tumor necrosis factor α therapy and a shorter time to relapse after stopping anti-tumor necrosis factor α therapy after obtaining sustained clinical remission. Overall, the investigators hypothesize that subclinical gut inflammation is an important predictor in therapy response and outcome. These data could provide better insights into the complex interactions between gut and joint inflammation and guide the physicians in the therapeutic approach.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Golimumab
Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped. All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission.
Also known as: ileocoloscopy
Proportion of Patients Achieving Sustained Clinical Remission
The proportion of patients who completed the trial and achieved Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) \< 1.3 recorded on 2 consecutive visits with at least 12 weeks interval. ASDAS-CRP was measured at every study visit, i.e. baseline, week 2, week 4, week 16, week 28, week 40 and week 52. The study endpoint could earliest be achieved at visit week 28.
Time frame: Upon end of trial for individual patient, between 28 and 52 weeks.
The Proportion of Patients With Healed Lesions of the Intestinal Mucosa
According to the protocol, every patient underwent ileocolonoscopy at baseline to screen for macroscopic and microscopic (histopathologic analysis of endoscopic biopsies) signs of inflammation. If baseline ileocolonoscopy was protocolled as positive, the patient would undergo a second ileocolonoscopic assessment at the timepoint of reaching sustained clinical remission (study endpoint). The outcome measure is the proportion of patients with a negative second ileocolonoscopy.
Time frame: At reaching primary outcome (between week 24 and week 52)
Recruitment period: November 2017 - December 2022 across 3 centres: * Gent University Hospital * Imelda Hospital in Bonheiden * Jessa Hospital in Hasselt
| Milestone | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Started | 64 |
| Treatment protocol initiated | 58 |
| Completed | 55 |
| Not completed | 9 |
| Withdrew: Screen failure | 6 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Adverse event | 1 |
The proportion of patients who completed the trial and achieved Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) \< 1.3 recorded on 2 consecutive visits with at least 12 weeks interval. ASDAS-CRP was measured at every study visit, i.e. baseline, week 2, week 4, week 16, week 28, week 40 and week 52. The study endpoint could earliest be achieved at visit week 28.
| Participants | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Proportion of Patients Achieving Sustained Clinical Remission | 34 |
According to the protocol, every patient underwent ileocolonoscopy at baseline to screen for macroscopic and microscopic (histopathologic analysis of endoscopic biopsies) signs of inflammation. If baseline ileocolonoscopy was protocolled as positive, the patient would undergo a second ileocolonoscopic assessment at the timepoint of reaching sustained clinical remission (study endpoint). The outcome measure is the proportion of patients with a negative second ileocolonoscopy.
| Participants | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| The Proportion of Patients With Healed Lesions of the Intestinal Mucosa | 0 |
Collected over Adverse events data was collected between the first dose administration of trial medication and the last trial related activity (through study completion, between 24 weeks and 52 weeks). Medical events that occurred between signing of the Informed Consent and the first intake of trial medication were documented as medical and surgical history section and concomitant diseases.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: NSAIDs With Possible Step-up to Golimumab | 0/58 (0%) | 0/58 (0%) | 19/58 (32.8%) |
| Event | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| NasopharyngitisInfections and infestations | 14/58 |
| GastroenteritisInfections and infestations | 4/58 |
| OtitisInfections and infestations | 3/58 |
Patients included in the trial and for whom the treatment protocol was initiated.
| Age, Continuous(years) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Mean | 28.2 ± 6.3 |
| Sex: Female, Male(Participants) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Female | 24 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 56 |
| Unknown or Not Reported | 2 |
| Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP(units on a scale) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Mean | 3.0 ± 0.9 |
| Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)(units on a scale) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Mean | 4.5 ± 1.5 |
| Bath Ankylosing Spondylitis Functional index (BASFI)(units on a scale) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Mean | 3.0 ± 2.2 |
| Positive for HLA-B27 (%)(Participants) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Count of participants | 50 |
| Body mass index (BMI)(kg/m^2) | Arm 1: NSAIDs With Possible Step-up to Golimumab |
|---|---|
| Mean | 23.3 ± 4.7 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2017 to primary completion in Dec 2023, 73 months.
Results were first posted in Feb 2025, 1 year 1 month after primary completion.
Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 73 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golimumab